Advertisement

Gastric Cancer

, Volume 21, Issue 4, pp 672–679 | Cite as

Indication for endoscopic treatment based on the risk of lymph node metastasis in patients with Siewert type II/III early gastric cancer

  • Jeung Hui Pyo
  • Hyuk Lee
  • Yang Won Min
  • Byung-Hoon Min
  • Jun Haeng Lee
  • Kyoung-Mee Kim
  • Heejin Yoo
  • Soohyun Ahn
  • Jae J. Kim
Original Article

Abstract

Background

Because of the poor prognosis of proximal gastric cancers, there is debate as to whether the conventional indications for endoscopic resection can be used.

Methods

Among subjects who underwent surgery for esophagogastric junction or gastric cardia cancer, 256 patients with T1 type II/III of the Siewert classification were included in this study. The association of lymph node metastasis (LNM) with each variable was analyzed using logistic regression models. A receiver operating characteristic curve was used to determine the discriminatory ability of the model. Propensity score-matched non-cardia cancer patients were selected to compare LNM and long-term survival rates.

Results

Of the 256 patients with T1 Siewert II/III gastric cancer, 21 (8.2%) had LNM. Because there was no LNM in T1a cancers, risk factors were analyzed only in patients with T1b. Tumor size (OR 1.42, 95% CI 1.10–1.82, P = 0.007) and lymphovascular invasion (LVI) (OR 5.13, 95% CI 1.88–14.06, P = 0.002) were determined to be predictors of LNM (sensitivity = 66.7% and specificity = 81.6%). Among patients without LVI, the groups with negligible risk for LNM were mucosa-confined cancer, or SM1 cancer with a tumor size ≤3 cm. No LNM was observed in patients satisfying the absolute or extended criteria for endoscopic resection of early gastric cancers. LNM and long-term survival rates of patients with Siewert II/III did not differ significantly compared with matched non-cardia cancer patients.

Conclusions

Tumor size and LVI were associated with LNM in patients with early Siewert type II/III gastric cancer, and the expanded indication for endoscopic resection may be used.

Keywords

Early gastric cancer Siewert type II/III Endoscopic resection Lymph node metastasis 

Notes

Compliance with ethical standards

Conflict of interest

There are no conflicts of interest to declare.

Ethical approval

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Because of the retrospective nature of the study, the requirement for informed consent was waived.

Supplementary material

10120_2017_789_MOESM1_ESM.tif (2.1 mb)
Online Resource 1. Distribution of lymph node metastasis in T1 Siewert II/III gastric cancer (TIFF 2139 kb)
10120_2017_789_MOESM2_ESM.docx (20 kb)
Online Resource 2 Lymph node metastasis in patients with Siewert II/III cancers and matched non-cardia T1 cancers (DOCX 19 kb)
10120_2017_789_MOESM3_ESM.tif (987 kb)
Online Resource 3. Overall survival in T1 Siewert II/III gastric cancer and matched non-cardia cancer (TIFF 987 kb)
10120_2017_789_MOESM4_ESM.tif (911 kb)
Online Resource 4. Disease-specific survival in T1 Siewert II/III gastric cancer and matched non-cardia cancer (TIFF 911 kb)
10120_2017_789_MOESM5_ESM.tif (1 mb)
Online Resource 5. Recurrence-free survival in T1 Siewert II/III gastric cancer and matched non-cardia cancer (TIFF 1057 kb)

References

  1. 1.
    Oda I, Abe S, Kusano C, Suzuki H, Nonaka S, Yoshinaga S, et al. Correlation between endoscopic macroscopic type and invasion depth for early esophagogastric junction adenocarcinomas. Gastric Cancer. 2011;14:22–7.CrossRefPubMedGoogle Scholar
  2. 2.
    Griffin SM, Burt AD, Jennings NA. Lymph node metastasis in early esophageal adenocarcinoma. Ann Surg. 2011;254:731–6 (discussion 6–7).CrossRefPubMedGoogle Scholar
  3. 3.
    Shah MA, Kelsen DP. Gastric cancer: a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease. J Natl Compr Canc Netw. 2010;8:437–47.CrossRefPubMedGoogle Scholar
  4. 4.
    McColl KE, Going JJ. Aetiology and classification of adenocarcinoma of the gastro-oesophageal junction/cardia. Gut. 2010;59:282–4.CrossRefPubMedGoogle Scholar
  5. 5.
    Petrelli F, Ghidini M, Barni S, Steccanella F, Sgroi G, Passalacqua R, et al (2017) Prognostic role of primary tumor location in non-metastatic gastric cancer: a systematic review and meta-analysis of 50 studies. Ann Surg Oncol 24(9):2655–68.CrossRefPubMedGoogle Scholar
  6. 6.
    Saito H, Fukumoto Y, Osaki T, Fukuda K, Tatebe S, Tsujitani S, et al. Distinct recurrence pattern and outcome of adenocarcinoma of the gastric cardia in comparison with carcinoma of other regions of the stomach. World J Surg. 2006;30:1864–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29:1715–21.CrossRefPubMedGoogle Scholar
  8. 8.
    Siewert JR, Stein HJ. Carcinoma of the cardia: carcinoma of the gastroesophageal junction: classification, pathology and extent of resection. Dis Esophagus. 1996;9:173–82.CrossRefGoogle Scholar
  9. 9.
    Biondi A, Hyung WJ. Seventh edition of TNM classification for gastric cancer. J Clin Oncol. 2011;29:4338–9 (author reply 40–42).CrossRefPubMedGoogle Scholar
  10. 10.
    Goto H, Tokunaga M, Miki Y, Makuuchi R, Sugisawa N, Tanizawa Y, et al. The optimal extent of lymph node dissection for adenocarcinoma of the esophagogastric junction differs between Siewert type II and Siewert type III patients. Gastric Cancer. 2015;18:375–81.CrossRefGoogle Scholar
  11. 11.
    Gotoda T. Endoscopic resection of early gastric cancer. Gastric Cancer. 2007;10:1–11.CrossRefPubMedGoogle Scholar
  12. 12.
    Gong EJ, Kim DH, Ahn JY, Jung KW, Lee JH, Choi KD, et al. Comparison of long-term outcomes of endoscopic submucosal dissection and surgery for esophagogastric junction adenocarcinoma. Gastric Cancer. 2017;20:84–91.CrossRefPubMedGoogle Scholar
  13. 13.
    Pyo JH, Lee H, Min BH, Lee JH, Choi MG, Lee JH, et al. Long-term outcome of endoscopic resection vs. surgery for early gastric cancer: a non-inferiority-matched cohort study. Am J Gastroenterol. 2016;111:240–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg. 1998;85:1457–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines (ver. 4). Gastric Cancer. 2014;2017(20):1–19.Google Scholar
  16. 16.
    Kim HH, Hyung WJ, Cho GS, Kim MC, Han SU, Kim W, et al. Morbidity and mortality of laparoscopic gastrectomy versus open gastrectomy for gastric cancer: an interim report: a phase III multicenter, prospective, randomized Trial (KLASS Trial). Ann Surg. 2010;251:417–20.CrossRefPubMedGoogle Scholar
  17. 17.
    AJCC. Cancer staging manual. 7th ed. New York: Springer; 2010.Google Scholar
  18. 18.
    Hirasawa K, Kokawa A, Oka H, Yahara S, Sasaki T, Nozawa A, et al. Superficial adenocarcinoma of the esophagogastric junction: long-term results of endoscopic submucosal dissection. Gastrointest Endosc. 2010;72:960–6.CrossRefPubMedGoogle Scholar
  19. 19.
    Hoteya S, Matsui A, Iizuka T, Kikuchi D, Yamada A, Yamashita S, et al. Comparison of the clinicopathological characteristics and results of endoscopic submucosal dissection for esophagogastric junction and non-junctional cancers. Digestion. 2013;87:29–33.CrossRefPubMedGoogle Scholar
  20. 20.
    Omae M, Fujisaki J, Horiuchi Y, Yoshizawa N, Matsuo Y, Kubota M, et al. Safety, efficacy, and long-term outcomes for endoscopic submucosal dissection of early esophagogastric junction cancer. Gastric Cancer. 2013;16:147–54.CrossRefPubMedGoogle Scholar
  21. 21.
    Yamada M, Oda I, Nonaka S, Suzuki H, Yoshinaga S, Taniguchi H, et al. Long-term outcome of endoscopic resection of superficial adenocarcinoma of the esophagogastric junction. Endoscopy. 2013;45:992–6.CrossRefPubMedGoogle Scholar
  22. 22.
    Zhang M, Li Z, Ma Y, Zhu G, Zhang H, Xue Y. Prognostic predictors of patients with carcinoma of the gastric cardia. Hepatogastroenterology. 2012;59:930–3.CrossRefPubMedGoogle Scholar
  23. 23.
    Maeda H, Okabayashi T, Nishimori I, Sugimoto T, Namikawa T, Dabanaka K, et al. Clinicopathologic features of adenocarcinoma at the gastric cardia: is it different from distal cancer of the stomach? J Am Coll Surg. 2008;206:306–10.CrossRefPubMedGoogle Scholar
  24. 24.
    Okholm C, Svendsen LB, Achiam MP. Status and prognosis of lymph node metastasis in patients with cardia cancer: a systematic review. Surg Oncol. 2014;23:140–6.CrossRefPubMedGoogle Scholar
  25. 25.
    Chen WY, Cheng HC, Wang JD, Sheu BS. Factors that affect life expectancy of patients with gastric adenocarcinoma. Clin Gastroenterol Hepatol. 2013;11:1595–600.CrossRefPubMedGoogle Scholar
  26. 26.
    Yamashita H, Katai H, Morita S, Saka M, Taniguchi H, Fukagawa T. Optimal extent of lymph node dissection for Siewert type II esophagogastric junction carcinoma. Ann Surg. 2011;254:274–80.CrossRefPubMedGoogle Scholar
  27. 27.
    Arigami T, Uenosono Y, Yanagita S, Nakajo A, Ishigami S, Okumura H, et al. Clinical significance of lymph node micrometastasis in gastric cancer. Ann Surg Oncol. 2013;20:515–21.CrossRefPubMedGoogle Scholar

Copyright information

© The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2017

Authors and Affiliations

  1. 1.Center for Health PromotionSamsung Medical CenterSeoulRepublic of Korea
  2. 2.Department of MedicineSamsung Medical Center, Sungkyunkwan University School of MedicineSeoulRepublic of Korea
  3. 3.Department of PathologySamsung Medical Center, Sungkyunkwan University School of MedicineSeoulRepublic of Korea
  4. 4.Statistics and Data Center, Research Institute for Future MedicineSamsung Medical CenterSeoulRepublic of Korea

Personalised recommendations